Výsledky vyhľadávania - "Anti-HIV Agents/therapeutic use"

Upresniť hľadanie
  1. 1
  2. 2
  3. 3

    Zdroj: Heje, K B, Lindhardt, M S, Meddis, A, Knudsen, A, Kronborg, G, Weis, N, Lebech, A-M, Kirk, O, Helweg-Larsen, J, Helms, M, Fischer, C P, Hansen, A-B E, Møller, S, Siebner, H R, Hove, J D, Gerstoft, J & Benfield, T 2025, ' No changes in weight, body composition or metabolic parameters after the switch to dolutegravir and lamivudine compared to continued treatment with dolutegravir, abacavir and lamivudine for virologically suppressed HIV infection (The AVERTAS trial) ', BMC Infectious Diseases, vol. 25, 1100 . https://doi.org/10.1186/s12879-025-11334-2

    Popis súboru: application/pdf

  4. 4
  5. 5

    Zdroj: AIDS Behav
    AIDS and behavior
    r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
    Instituto de Investigación Sanitaria La Fe (IIS La Fe)

  6. 6

    Zdroj: Virdee, A K, Knudtzen, F C, Llibre, J M, Omland, L H, Obel, N, Stærke, N B, Åhsberg, J, Ørsted, I, Kronborg, G, Mohey, R, Montejo, M D P F, Johansen, I S & Martin-Iguacel, R 2024, 'Risk of tuberculosis after achieving HIV virological suppression on antiretroviral therapy: a Danish nationwide prospective cohort study', Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae499
    Virdee, A K, Knudtzen, F C, Llibre, J M, Omland, L H, Obel, N, Stærke, N B, Åhsberg, J, Ørsted, I, Kronborg, G, Mohey, R, Montejo, M D P F, Johansen, I S & Martin-Iguacel, R 2025, 'Risk of Tuberculosis After Achieving HIV Virological Suppression on Antiretroviral Therapy : A Danish Nationwide Prospective Cohort Study', Clinical Infectious Diseases, vol. 80, no. 4, pp. 854-863. https://doi.org/10.1093/cid/ciae499

  7. 7
  8. 8

    Zdroj: AIDS Behav
    AIDS AND BEHAVIOR
    r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia
    Fundación de Investigación del Hospital General de Valencia (FIHGUV)

  9. 9

    Zdroj: ATHENA National Observational Cohort Study 2024, 'Real-world effectiveness and tolerability of switching to doravirine-based antiretroviral therapy in people with HIV : a nationwide, matched, prospective cohort study', The Lancet HIV, vol. 11, no. 9, pp. e576-e585. https://doi.org/10.1016/S2352-3018(24)00150-4
    The Lancet HIV, 11, 9, pp. e576-e585

    Popis súboru: application/pdf

  10. 10

    Prispievatelia: Trickey, Adam Zhang, Lei Rentsch, Christopher T a ďalší

    Zdroj: AIDS
    Repisalud
    Instituto de Salud Carlos III (ISCIII)
    AIDS, vol. 38, no. 10, pp. 1533-1542

    Popis súboru: application/pdf

  11. 11
  12. 12
  13. 13

    Zdroj: Clinical Infectious Diseases, 79, 5, pp. 1242-1257
    Tusch, E, Ryom, L, Pelchen-Matthews, A, Mocroft, A, Elbirt, D, Oprea, C, Günthard, H F, Staehelin, C, Zangerle, R, Suarez, I, Vehreschild, J J, Wit, F, Menozzi, M, d'Arminio Monforte, A, Spagnuolo, V, Pradier, C, Carlander, C, Suanzes, P, Wasmuth, J-C, Carr, A, Petoumenos, K, Borgans, F, Bonnet, F, De Wit, S, El-Sadr, W, Neesgaard, B, Jaschinski, N, Greenberg, L, Hosein, S R, Gallant, J, Vannappagari, V, Young, L, Sabin, C, Lundgren, J, Peters, L, Reekie, J & D:A:D cohort study 2024, 'Trends in Mortality in People With HIV From 1999 through 2020 : a multi-cohort collaboration', Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol. 79, no. 5, pp. 1242-1257. https://doi.org/10.1093/cid/ciae228

    Popis súboru: application/pdf

  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20

    Zdroj: Brown, J A, Motaboli, L, Lerotholi, M, Kohler, M, Haenggi, K, Mokete, M, Chakela, M G, Kao, M, Kopo, M, Mokebe, M, Urda, L, Nsakala, B L, Lukau, B, Ayakaka, I, Amstutz, A, Ehmer, J, Klicpera, A, Klimkait, T, Glass, T, Muhairwe, J, Chammartin, F, Tschumi, N & Labhardt, N D 2025, 'Cohort profile : the Viral load Cohort North-East Lesotho (VICONEL) from 2016 to 2023 - cohort description, test volumes, predictors of viraemia and the road ahead', BMJ Open, vol. 15, no. 2, e085404. https://doi.org/10.1136/bmjopen-2024-085404